Coya Therapeutics Inc. (NASDAQ:COYA) on Tuesday announced results from a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination, in an in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback